ConductScience.org, home

Paper40511544

Beyond the tumor microenvironment: Orchestrating systemic T‑cell response for next‑generation cancer immunotherapy (Review).

Lyu X and 4 others. Int J Oncol, 2025. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Beyond the tumor microenvironment: Orchestrating systemic T‑cell response for next‑generation cancer immunotherapy (Review). Papers, record 40511544. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40511544

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Beyond the tumor microenvironment: Orchestrating systemic T‑cell response for next‑generation cancer immunotherapy (Review).
PubMed
Journal
Int J Oncol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
4
iCite
Revised in PubMed
2025-07-04
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lyu XXiaohong
2Han JJiashu
3Lin CChen
4Zhou YYidong
5Wang WWeibin

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Tumor MicroenvironmentMajor topic
NeoplasmsMajor topic
ImmunotherapyMajor topic
CD8-Positive T-LymphocytesMajor topic
T-LymphocytesMajor topic
Humans
Immune Checkpoint Inhibitors
Animals
Lymphocytes, Tumor-Infiltrating

Source PubMed

Download CSV of topics

References260

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118765557CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.Clin Cancer Res2008https://conductscience.org/library/papers/18765557PubMed
229443960TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.Nature2018https://conductscience.org/library/papers/29443960PubMed
328928380Predictors of responses to immune checkpoint blockade in advanced melanoma.Nat Commun2017https://conductscience.org/library/papers/28928380PubMed
429769722Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates.Nature2018https://conductscience.org/library/papers/29769722PubMed
528423487Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.Oncotarget2017https://conductscience.org/library/papers/28423487PubMed
637008996Migration of stem-like CD8 T cells between tissue microenvironments underpins successful anti-tumour immune responses.Discov Immunol2023https://conductscience.org/library/papers/37008996PubMed
735120598Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy.Cancer Cell2022https://conductscience.org/library/papers/35120598PubMed
833178203Localized Interleukin-12 for Cancer Immunotherapy.Front Immunol2020https://conductscience.org/library/papers/33178203PubMed
934031618Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity.Nat Immunol2021https://conductscience.org/library/papers/34031618PubMed
1037046094Antibodies against endogenous retroviruses promote lung cancer immunotherapy.Nature2023https://conductscience.org/library/papers/37046094PubMed
1118797453Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.Mol Ther2008https://conductscience.org/library/papers/18797453PubMed
1235593358Clinical Combinatorial Treatments Based on Cancer Vaccines: Combination with Checkpoint Inhibitors and Beyond.Curr Drug Targets2022https://conductscience.org/library/papers/35593358PubMed
1330647082The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors.Clin Cancer Res2019https://conductscience.org/library/papers/30647082PubMed
1428167454Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients.Eur J Cancer2017https://conductscience.org/library/papers/28167454PubMed
1535472220In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue.J Exp Med2022https://conductscience.org/library/papers/35472220PubMed
1634516744Tumor-draining lymph nodes: At the crossroads of metastasis and immunity.Sci Immunol2021https://conductscience.org/library/papers/34516744PubMed
1731275310Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma.Front Immunol2019https://conductscience.org/library/papers/31275310PubMed
1833055204Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors.J Immunother Cancer2020https://conductscience.org/library/papers/33055204PubMed
1926989092Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.Int Immunol2016https://conductscience.org/library/papers/26989092PubMed
2027178742Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab.Clin Cancer Res2016https://conductscience.org/library/papers/27178742PubMed

See all 260 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42317337STAT6 inhibition of M2 macrophages suppresses tumor growth by modulating the tumor microenvironment in colon cancer model.Front Immunol2026https://conductscience.org/library/papers/42317337PubMed
41928274Organ-Specific Migration License (OSML) theory: a novel paradigm for spatiotemporal regulation and intervention of cross-organ immune cell migration in tumor immune responses.Cell Commun Signal2026https://conductscience.org/library/papers/41928274PubMed
41601689Terminally exhausted CD8+ T cells in solid tumors: biology, biomarker potential and translational tools for precision oncology.Front Immunol2025https://conductscience.org/library/papers/41601689PubMed
41153357Spotlight on FAM72B: Pan-Cancer Expression Profiles and Its Potential as a Prognostic and Immunotherapeutic Biomarker.Genes (Basel)2025https://conductscience.org/library/papers/41153357PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40511544

GET https://conductscience.org/api/papers/v1/40511544/references?page=2